ATE423575T1 - Zusammensetzungen von magnetischen partikeln mit gem-biphosphonate derivaten beschichtet - Google Patents

Zusammensetzungen von magnetischen partikeln mit gem-biphosphonate derivaten beschichtet

Info

Publication number
ATE423575T1
ATE423575T1 AT03799680T AT03799680T ATE423575T1 AT E423575 T1 ATE423575 T1 AT E423575T1 AT 03799680 T AT03799680 T AT 03799680T AT 03799680 T AT03799680 T AT 03799680T AT E423575 T1 ATE423575 T1 AT E423575T1
Authority
AT
Austria
Prior art keywords
gem
magnetic particles
biphosphonate
derivatives
compositions
Prior art date
Application number
AT03799680T
Other languages
English (en)
Inventor
Marc Port
Claire Corot
Isabelle Raynal
Olivier Rousseaux
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Application granted granted Critical
Publication of ATE423575T1 publication Critical patent/ATE423575T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT03799680T 2002-12-20 2003-12-19 Zusammensetzungen von magnetischen partikeln mit gem-biphosphonate derivaten beschichtet ATE423575T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0216410A FR2848850B1 (fr) 2002-12-20 2002-12-20 Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates.

Publications (1)

Publication Number Publication Date
ATE423575T1 true ATE423575T1 (de) 2009-03-15

Family

ID=32406319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03799680T ATE423575T1 (de) 2002-12-20 2003-12-19 Zusammensetzungen von magnetischen partikeln mit gem-biphosphonate derivaten beschichtet

Country Status (14)

Country Link
US (2) US7780953B2 (de)
EP (1) EP1572246B1 (de)
JP (1) JP4638738B2 (de)
CN (1) CN100358584C (de)
AT (1) ATE423575T1 (de)
AU (1) AU2003299388A1 (de)
BR (1) BR0316886A (de)
CA (1) CA2510531C (de)
DE (1) DE60326383D1 (de)
DK (1) DK1572246T3 (de)
ES (1) ES2321709T3 (de)
FR (1) FR2848850B1 (de)
PT (1) PT1572246E (de)
WO (1) WO2004058275A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) * 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
WO2003067219A2 (en) * 2002-02-07 2003-08-14 The General Hospital Corporation STRUCTURE OF INTEGRIN αV-β3 EXTRACELLULAR DOMAIN COMPLEXED WITH LIGAND
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
FR2856689A1 (fr) * 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
US8118754B1 (en) 2007-11-15 2012-02-21 Flynn Edward R Magnetic needle biopsy
US20050251233A1 (en) * 2004-05-07 2005-11-10 John Kanzius System and method for RF-induced hyperthermia
US7510555B2 (en) * 2004-05-07 2009-03-31 Therm Med, Llc Enhanced systems and methods for RF-induced hyperthermia
US20070250139A1 (en) * 2004-05-07 2007-10-25 John Kanzius Enhanced systems and methods for RF-induced hyperthermia II
US7627381B2 (en) * 2004-05-07 2009-12-01 Therm Med, Llc Systems and methods for combined RF-induced hyperthermia and radioimmunotherapy
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US9964469B2 (en) 2005-02-28 2018-05-08 Imagion Biosystems, Inc. Magnetic needle separation and optical monitoring
US7598199B2 (en) * 2005-05-10 2009-10-06 Massachusetts Institute Of Technology Catalytic nanoparticles for nerve-agent destruction
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
FR2904784B1 (fr) * 2006-08-10 2010-09-03 Surfactis Technologies Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations
US8447379B2 (en) 2006-11-16 2013-05-21 Senior Scientific, LLC Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2921838A1 (fr) * 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
FR2921837B1 (fr) * 2007-10-05 2015-07-31 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice organique couplee a des ligands de ciblage
BRPI0908448A2 (pt) * 2008-03-17 2019-09-24 Cabot Corp pigmentos modificados tendo liberação de fosfato reduzida, e dispersões e composições de tinta para jato de tinta com os mesmos
US8057976B2 (en) * 2008-08-21 2011-11-15 Empire Technology Development Llc Method for producing toner
US9205155B2 (en) * 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
KR20120087165A (ko) 2009-11-06 2012-08-06 사이언티픽 나노메디슨, 아이엔씨. 표적화된 나노입자 및 그것의 자기 특성을 사용하는 암 및 다른 생물학적 물질과 같은 세포의 검출, 측정 및 이미징
US10194825B2 (en) 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
EP2595762A4 (de) * 2010-07-21 2015-11-04 Rhodia China Co Ltd Verfahren zur beschichtung eines anorganischen substrats mit einer stabilen organischen schicht
KR101805873B1 (ko) 2011-08-03 2018-01-10 한화케미칼 주식회사 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
CA2819795A1 (en) * 2010-12-15 2012-06-21 General Electric Company Nanoparticle composition and associated methods thereof
EP2572736A1 (de) * 2011-09-23 2013-03-27 Spago Imaging AB Mangan-enthaltende Nanostrukturen
FR2990433A1 (fr) * 2012-05-10 2013-11-15 Surfactis Technologies Compositions catanioniques de recouvrement de surface par des molecules phosphoniques et amines
CN105524492A (zh) * 2016-01-12 2016-04-27 四川大学 一种简易低成本的磁性微粒表面活性基团引入方法
CN108203448B (zh) * 2016-12-19 2020-12-15 香港中文大学 促进矿化并提供生物活性离子的持续释放的可注射水凝胶
CN111840547B (zh) * 2020-06-15 2023-04-28 山西振东泰盛制药有限公司 注射用培美曲塞磁性自组装纳米复合颗粒制备方法
WO2025094171A1 (en) * 2023-11-02 2025-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Superhydrophobic coating

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440646A (en) * 1965-08-24 1984-04-03 Plains Chemical Development Co. Chelation
GB1435295A (en) * 1973-11-19 1976-05-12 Research Corp Bone seeking technetium-99m complex
US4120890A (en) * 1976-01-21 1978-10-17 Henkel Kommanditgesellschaft Auf Aktien Diphosphonoalkane carboxylic acids, process of preparation and methods of use
FR2461521A1 (fr) * 1979-07-20 1981-02-06 Anvar Fluides magnetiques, notamment ferrofluides, et procede pour leur obtention
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5928958A (en) * 1994-07-27 1999-07-27 Pilgrimm; Herbert Superparamagnetic particles, process for their manufacture and usage
AU4569496A (en) * 1995-02-24 1996-09-05 Bristol-Myers Squibb Company Tetralinyl- and indanyl-ethylamides
FR2736197B1 (fr) * 1995-06-29 1997-09-12 Univ Paris Curie Nanoparticules magnetiques couplees a de l'annexine et leur utilisation
WO1999041613A1 (en) * 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6514481B1 (en) * 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10016559A1 (de) * 2000-04-03 2001-10-18 Eucro Europe Contract Res Gmbh System für den Transport von Aktivstoffen in einem biologischen System
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues

Also Published As

Publication number Publication date
JP4638738B2 (ja) 2011-02-23
AU2003299388A1 (en) 2004-07-22
CN1744920A (zh) 2006-03-08
US7780953B2 (en) 2010-08-24
EP1572246A2 (de) 2005-09-14
WO2004058275A2 (fr) 2004-07-15
FR2848850A1 (fr) 2004-06-25
BR0316886A (pt) 2005-10-25
CA2510531C (fr) 2012-09-04
CN100358584C (zh) 2008-01-02
US20100297025A1 (en) 2010-11-25
US20040253181A1 (en) 2004-12-16
JP2006513198A (ja) 2006-04-20
WO2004058275A3 (fr) 2004-12-09
FR2848850B1 (fr) 2005-06-24
PT1572246E (pt) 2009-05-22
DK1572246T3 (da) 2009-06-08
CA2510531A1 (fr) 2004-07-15
DE60326383D1 (de) 2009-04-09
AU2003299388A8 (en) 2004-07-22
ES2321709T3 (es) 2009-06-10
EP1572246B1 (de) 2009-02-25

Similar Documents

Publication Publication Date Title
DE60326383D1 (de) Zusammensetzungen von magnetischen partikeln mit gem-biphosphonate derivaten beschichtet
AU3599801A (en) Reagents for the quantitation of active oxygen
CO5251404A1 (es) Compuestos antibioticos de azalida
PH12009501118A1 (en) Chemical compounds
WO2005042444A3 (ja) 白金錯体及び発光素子
WO2005042444A1 (ja) 白金錯体及び発光素子
MXPA04006581A (es) Derivados de sulfonato y su empleo como acidos latentes.
BR0108745A (pt) Revestimentos de barreira tendo bis-silanos
TR200401021T4 (tr) Oksidasyonla kuruyan çoklu doymamış bir yoğuşturma ürünü, bir politiol ve bir kurutucu içeren kaplama bileşimi
MXPA04004347A (es) Nuevos fotoindicadores difuncionales.
DE60123933D1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
MXPA04004814A (es) Metodos para descubrir ligandos.
MXPA05011847A (es) Revestimientos fotocurados y estabilizados.
SE0004245D0 (sv) Novel compounds and their use
BR0003072A (pt) Fechadura de cilindro dotada de meios de orientação magneticamente operados
AU5215800A (en) Binding agents modified by nanoparticles for coating agents and use of the same
ATE166047T1 (de) Neue verbindungen mit blutplättchenaggregationshemmender aktivität
EP1398306A3 (de) Ein (1'R,2'S,5'R)-3-l-Menthoxypropan-1-ol, das eine kühlende Empfindung erzeugt
CA2022187A1 (en) N,n-bis-phosphonomethyl taurine n-oxide and water-soluble salts thereof
MY144165A (en) Antiskinning compound and compositions containing them
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
PT1140942E (pt) Inibidores da prenil-transferase
TR200001819T2 (tr) COPD tedavi yöntemi.
BRPI0206922B8 (pt) composto de fragrância, composição de fragrância contendo o mesmo, e método para preparação de um composto de fragrância
DE50203353D1 (de) 1,3-dihydroxybenzol-derivate und diese verbindungen enthaltende färbemittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572246

Country of ref document: EP